CONMEDCNMD
CNMD
About: Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
Employees: 4,000
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
731% more call options, than puts
Call options by funds: $8.3M | Put options by funds: $999K
5.99% more ownership
Funds ownership: 109.77% [Q3] → 115.76% (+5.99%) [Q4]
0% more capital invested
Capital invested by funds: $2.43B [Q3] → $2.44B (+$8.62M) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 98
10% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 42
4% less funds holding
Funds holding: 286 [Q3] → 275 (-11) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
12%
upside
Avg. target
$72
46%
upside
High target
$91
85%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
Stifel Rick Wise 30% 1-year accuracy 10 / 33 met price target | 12%upside $55 | Hold Downgraded | 28 Apr 2025 |
Wells Fargo Vik Chopra 36% 1-year accuracy 4 / 11 met price target | 43%upside $70 | Equal-Weight Maintained | 6 Feb 2025 |
Needham Mike Matson 37% 1-year accuracy 44 / 120 met price target | 85%upside $91 | Buy Maintained | 6 Feb 2025 |
JP Morgan Robbie Marcus 41% 1-year accuracy 7 / 17 met price target | 43%upside $70 | Neutral Downgraded | 6 Feb 2025 |
Financial journalist opinion
Based on 7 articles about CNMD published over the past 30 days
Neutral
Seeking Alpha
5 hours ago
CONMED Corporation (CNMD) Q1 2025 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer and President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Matt O'Brien - Piper Sandler Robbie Marcus - JPMorgan Rick Wise - Stifel Young Li - Jefferies Travis Steed - Bank of America Mike Matson - Needham Operator Good day, and thank you for standing by. Welcome to CONMED's First Quarter Fiscal 2025 Earnings Conference Call.
Neutral
Zacks Investment Research
7 hours ago
Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
8 hours ago
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
Conmed (CNMD) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.79 per share a year ago.
Neutral
Business Wire
11 hours ago
CONMED Corporation Announces First Quarter 2025 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per sh.
Positive
Zacks Investment Research
2 weeks ago
4 Stocks to Watch as Dental Supplies Recovers Amid Tariff Headwind
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, MMSI, XRAY and CNMD.
Neutral
Zacks Investment Research
3 weeks ago
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Neutral
Business Wire
4 weeks ago
CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro.
Neutral
Business Wire
2 months ago
CONMED Corporation Adds Mark Kaye to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are extremely pleased to welcome Mark to the board,” said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. “Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a stro.
Neutral
Business Wire
2 months ago
CONMED Corporation Announces Quarterly Cash Dividend
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, includ.
Negative
Zacks Investment Research
2 months ago
New Strong Sell Stocks for February 19th
ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024.
Charts implemented using Lightweight Charts™